266 related articles for article (PubMed ID: 19129422)
1. Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009.
Geller JC; Egstrup K; Kulakowski P; Rosenqvist M; Jansson MA; Berggren A; Edvardsson N; Sager P; Crijns HJ
J Clin Pharmacol; 2009 Mar; 49(3):312-22. PubMed ID: 19129422
[TBL] [Abstract][Full Text] [Related]
2. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009.
Crijns HJ; Van Gelder IC; Walfridsson H; Kulakowski P; Rónaszéki A; Dedek V; Malm A; Almgren O
Heart Rhythm; 2006 Nov; 3(11):1321-31. PubMed ID: 17074639
[TBL] [Abstract][Full Text] [Related]
3. The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation.
Frick M; Darpö B; Ostergren J; Rosenqvist M
Eur Heart J; 2000 Jul; 21(14):1177-85. PubMed ID: 10924301
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
[TBL] [Abstract][Full Text] [Related]
5. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.
Roy D; Rowe BH; Stiell IG; Coutu B; Ip JH; Phaneuf D; Lee J; Vidaillet H; Dickinson G; Grant S; Ezrin AM; Beatch GN;
J Am Coll Cardiol; 2004 Dec; 44(12):2355-61. PubMed ID: 15607398
[TBL] [Abstract][Full Text] [Related]
6. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial.
Fetsch T; Bauer P; Engberding R; Koch HP; Lukl J; Meinertz T; Oeff M; Seipel L; Trappe HJ; Treese N; Breithardt G;
Eur Heart J; 2004 Aug; 25(16):1385-94. PubMed ID: 15302102
[TBL] [Abstract][Full Text] [Related]
7. Improvement in exercise performance after successful cardioversion in patients with persistent atrial fibrillation and symptoms of heart failure.
Wozakowska-Kapłon B; Opolski G
Kardiol Pol; 2003 Sep; 59(9):213-23. PubMed ID: 14618198
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously.
Rónaszéki A; Alings M; Egstrup K; Gaciong Z; Hranai M; Király C; Sereg M; Figatowski W; Bondarov P; Johansson S; Frison L; Edvardsson N; Berggren A
Europace; 2011 Aug; 13(8):1148-56. PubMed ID: 21561900
[TBL] [Abstract][Full Text] [Related]
9. Rapid slowing of the atrial fibrillatory rate after administration of AZD7009 predicts conversion of atrial fibrillation.
Aunes M; Egstrup K; Frison L; Berggren A; Stridh M; Sörnmo L; Edvardsson N
J Electrocardiol; 2014; 47(3):316-23. PubMed ID: 24508473
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
Stiell IG; Roos JS; Kavanagh KM; Dickinson G
Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
[TBL] [Abstract][Full Text] [Related]
11. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study.
Nergårdh AK; Rosenqvist M; Nordlander R; Frick M
Eur Heart J; 2007 Jun; 28(11):1351-7. PubMed ID: 17329409
[TBL] [Abstract][Full Text] [Related]
12. Ibutilide in persistent atrial fibrillation refractory to conventional cardioversion methods.
Naegeli B; Straumann E; Bertel O
Int J Cardiol; 2005 Mar; 99(2):283-7. PubMed ID: 15749188
[TBL] [Abstract][Full Text] [Related]
13. Magnesium sulfate versus placebo for paroxysmal atrial fibrillation: a randomized clinical trial.
Chu K; Evans R; Emerson G; Greenslade J; Brown A
Acad Emerg Med; 2009 Apr; 16(4):295-300. PubMed ID: 19207134
[TBL] [Abstract][Full Text] [Related]
14. [Immediate cardioversion of atrial fibrillation and atrial flutter lasting less than 90 days by ibutilide versus propafenone: a multicenter study].
Zhang HC; Guo JH; Fang Q; Zheng YA; Sun YM; Zhu WQ; Wan Z; Guo JX; Ge JB; Han SM
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(12):798-801. PubMed ID: 15949393
[TBL] [Abstract][Full Text] [Related]
15. Amiodarone after unsuccessful direct-current cardioversion of persistent atrial fibrillation.
Kosior DA; Wozakowska-Kapłon B; Jasik M; Kiliszek M; Rabczenko D; Opolski G
Kardiol Pol; 2005 Dec; 63(6):585-92; discussion 593-4. PubMed ID: 16380855
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation.
Davey MJ; Teubner D
Ann Emerg Med; 2005 Apr; 45(4):347-53. PubMed ID: 15795711
[TBL] [Abstract][Full Text] [Related]
17. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.
Hongo RH; Themistoclakis S; Raviele A; Bonso A; Rossillo A; Glatter KA; Yang Y; Scheinman MM
J Am Coll Cardiol; 2004 Aug; 44(4):864-8. PubMed ID: 15312873
[TBL] [Abstract][Full Text] [Related]
18. Decrease of the atrial fibrillatory rate, increased organization of the atrial rhythm and termination of atrial fibrillation by AZD7009.
Aunes-Jansson M; Edvardsson N; Stridh M; Sörnmo L; Frison L; Berggren A
J Electrocardiol; 2013; 46(1):29-35. PubMed ID: 23219385
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study.
Almroth H; Höglund N; Boman K; Englund A; Jensen S; Kjellman B; Tornvall P; Rosenqvist M
Eur Heart J; 2009 Apr; 30(7):827-33. PubMed ID: 19202157
[TBL] [Abstract][Full Text] [Related]
20. Increase in QT/QTc dispersion after low energy cardioversion of chronic persistent atrial fibrillation.
Boriani G; Valzania C; Biffi M; Corazza I; Camanini C; Martignani C; Bacchi L; Zannoli R; Branzi A
Int J Cardiol; 2004 Jun; 95(2-3):245-50. PubMed ID: 15193827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
